Local ablation of hepatocellular carcinoma by interstitial brachytherapy: prediction of outcome by diffusion-weighted imaging

Thormann, Maximilian; Surov, Alexey; Pech, Maciej; March, Christine; Hass, Peter; Damm, Robert; Omari, Jazan

doi:10.1177/02841851221129714

Cited by 1 publication

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatments in center 2 were performed between 2014 and 2018 (a longer recruitment period due to the longer existing therapy offer for HDR-BT). The patients recruited in center 2 were also part of the previously published study (21). However, the two studies address different questions and aims; the already published study analyzes the prognostic and predictive value of baseline DWI in HCC before HDR-BT with regard to local tumor control and overall survival.…”

Section: Study Populationmentioning

confidence: 99%

Diffusion-weighted MRI (DWI) for assessment of response to high-dose-rate CT-guided brachytherapy (HDR-BT) of hepatocellular carcinoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background High-dose-rate computed tomography (CT)-guided brachytherapy (HDR-BT) has shown promising results in patients with hepatocellular carcinoma (HCC). While growing evidence shows clear limitations of mRECIST, diffusion-weighted imaging (DWI) has relevant potential in improving the response assessment. Purpose To assess whether DWI allows evaluation of short- and long-term tumor response in patients with HCC after HDR-BT. Material and Methods A total of 22 patients with 11 non-responding HCCs (NR-HCC; local tumor recurrence within two years) and 24 responding HCCs (R-HCC; follow-up at least two years) were included in this retrospective bi-center study. HCCs were treated with HDR-BT and patients underwent pre- and post-interventional magnetic resonance imaging (MRI). Analyses of DWI were evaluated and compared between pre-interventional MRI, 1.follow-up after 3 months and 2.follow-up at the time of the local tumor recurrence (in NR-HCC) or after 12 months (in R-HCC). Results ADCmean of R-HCC increased significantly after HDR-BT on the first and second follow-up (ADCmean: 0.87 ± 0.18 × 10−3 mm2/s [pre-interventional]: 1.14 ± 0.23 × 10−3 mm2/s [1. post-interventional]; 1.42 ± 0.32 × 10−3 mm2/s [2. post-interventional]; P < 0.001). ADCmean of NR-HCC did not show a significant increase from pre-intervention to 1. post-interventional MRI (ADCmean: 0.85 ± 0.24 × 10−3 mm2/s and 1.00 ± 0.30 × 10−3 mm2/s, respectively; P = 0.131). ADCmean increase was significant between pre-intervention and 2. follow-up (ADCmean: 1.03 ± 0.19 × 10−3 mm2/s; P = 0.018). There was no significant increase of ADCmean between the first and second follow-up. There was, however, a significant increase of ADCmin after 12 months (ADCmin: 0.87 ± 0.29 × 10−3 mm2/s) compared to pre-interventional MRI and first follow-up ( P < 0.005) only in R-HCC. Conclusion The tumor response after CT-guided HDR-BT was associated with a significantly higher increase in ADCmean and ADCmin in short- and long-term follow-up.

show abstract

Section: Study Populationmentioning

confidence: 99%